Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: University of Michigan Rogel Cancer Center
Condition: Urothelial Carcinoma
NCT06356155
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.